Validation of a noninvasive prognostic signature for allograft failure following BK virus associated nephropathy. Issue 2 (21st January 2021)

• Record Type: Journal Article
• Authors: Abuhelaiqa, Essa; Snopkowski, Catherine; Li, Carol; Salvatore, Steve; Lee, John R.; Muthukumar, Thangamani; Lee, Jun B.; Hartono, Choli; Ding, Ruchuang; Seshan, Surya V.; Suthanthiran, Manikkam; Dadhania, Darshana M.
• Is Part Of: Clinical transplantation. Volume 35:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-01-21
• Subjects: BK virus nephropathy -- PAI‐1 -- Polyomavirus nephropathy -- urine mRNA; kidney transplant; graft failure; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.14200
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Identifying kidney transplant recipients at risk for graft failure following BK virus nephropathy (BKVN) may allow personalization of therapy. We have reported that a noninvasive composite signature of urinary cell level of plasminogen activator inhibitor‐1(PAI‐1) mRNA and serum creatinine level, measured at the time of BKVN diagnosis, is prognostic of graft failure. In this investigation, we determined whether the composite signature is prognostic of graft failure in an independent cohort of 25 patients with BKVN. Of the 25 patients, 8 developed graft failure and 17 did not. We measured urinary cell levels of PAI‐1 mRNA, 18S rRNA, and BKV VP1 mRNA at the time of BKVN diagnosis and evaluated clinical parameters including Banff pathology scores, acute rejection, and graft function. The area under the receiver operating characteristic curve for the noninvasive composite signature was 0.95 ( P < .001) for prognosticating graft failure. The previously reported threshold of −0.858 predicted graft failure with a sensitivity of 75% and a specificity of 94%. Our current study validates the use of composite signature and the threshold of −0.858 to identify those at risk for graft failure following BKVN diagnosis, and supports future studies utilizing the composite signature score to personalize treatment of BKVN.